Circulating micro ribonucleic acids in cardiovascular disease: a look beyond myocardial injury
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Laboratory markers are of significant clinical importance in the evaluation of patients with suspected cardiac diseases. They have evolved as essential tools in cardiology over the last 50 years, i.e., lipid testing for primary and secondary prevention, creatine kinase isoenzyme MB and subsequently the more sensitive and specific cardiac troponin (cTn) testing for the diagnosis and management of acute myocardial infarction (AMI), and more recently natriuretic peptide (NP) testing for the diagnosis (in particular exclusion), risk stratification, and monitoring of heart failure (HF) (1-3). We are beginning an era when it may be possible for biomarkers to direct treatment to optimize patient management. This is already the case with cTn (1,4) but should be the final goal with all cardiac biomarkers. However, there are still some open major clinical issues, e.g., the diagnosis of myocardial ischemia. Despite huge research efforts in recent years, which were triggered by the great clinical significance and economic impact of cardiac diseases, biomarkers for the prediction of coronary artery disease (CAD) and for risk stratification in stable CAD or the general population have not yet fulfilled their manifest promise so far (5). The most established marker in this respect is high-sensitivity C-reactive protein (hs-CRP) which still remains controversial (3,6).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Cited by
Zhang, Z., Ho, K. M., & Hong, Y. (2019) · Critical Care · doi:10.1186/s13054-019-2411-z · Cited by 331
Germline MC1R status influences somatic mutation burden in melanoma
Robles-Espinoza, C. D., Roberts, N. D., Chen, S., Leacy, F. P., Alexandrov, L. B., Pornputtapong, N., Halaban, R., Krauthammer, M., Cui, R., Timothy Bishop, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12064 · Cited by 124
Machine learning to guide the use of adjuvant therapies for breast cancer
Alaa, A. M., Gurdasani, D., Harris, A. L., Rashbass, J., & van der Schaar, M. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00353-8 · Cited by 55
Lu, X., Kang, H., Zhou, D., & Li, Q. (2022) · Scientific Reports · doi:10.1038/s41598-022-27134-6 · Cited by 31
Metadata
- Authors
- Mair, J.
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2016-10
- Volume
- 4
- Issue
- S1
- Pages
- S30-S30
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- OpenAlex
- W2550380542
- Cited by
- 55
- References
- 2
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating micro ribonucleic acids in cardiovascular disease: a look beyond myocardial injury. https://app.cochat.ai/papers/10.21037/atm.2016.10.67
- The paper
- Mair, J. (2016). Circulating micro ribonucleic acids in cardiovascular disease: a look beyond myocardial injury. Annals of Translational Medicine. https://doi.org/10.21037/atm.2016.10.67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.